BRAF and MEK inhibitors do not appear to be a promising therapeutic regimen for the treatment of melanoma patients with NRAS-mutated metastatic melanoma when applied at the currently used doses for the treatment of BRAFV600E/K melanoma. Here, MAP2K7 is linked to metastatic melanoma.